Bio/Pharma News

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

July 15, 2024

The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.

Pfizer and Evotec Partner for Drug Discovery

July 12, 2024

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

Roche to Reintroduce nAMD Treatment in US After FDA Approves Updates

July 08, 2024

Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards.

EU Makes First-in-World Approval of Dupixent as Targeted Therapy for Uncontrolled COPD

July 08, 2024

Other indications for which the Sanofi treatment has been approved include atopic dermatitis, asthma, and chronic rhinosinusitis.

GSK and CureVac Enter into Licensing Agreement

July 04, 2024

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Angelini Pharma Seeks Solutions for New Drug Delivery Systems and Treatments

July 02, 2024

The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.

GSK’s Application for Jemperli Plus Chemotherapy for Use in All Patients with Endometrial Cancer Accepted by EMA

July 02, 2024

GSK’s application for using Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer has been accepted by the EMA.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29, 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Roche Attains European Recommendation for Retinal Vein Occlusion Treatment

June 28, 2024

Vabysmo, already approved for patients with RVO in the US and Japan, would be the first bispecific antibody treatment for the condition in Europe.

Data from Study of Teva’s Ajovy Suggests Change to Migraine Treatment Pause Protocols

June 28, 2024

The typical cycle of ceasing and then reinitiating fremanezumab treatments may actually result in increased monthly migraine days, the study said.